Gaush Meditech Ltd — Board/Management Information 2023

Jan 10, 2023

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [197 x 34] intentionally omitted <==

Gaush Meditech Ltd 高視醫療科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2407)

(1) APPOINTMENT OF CO-CHIEF EXECUTIVE OFFICER; (2) APPOINTMENT OF CHIEF FINANCIAL OFFICER; AND

(3) RESIGNATION OF PRESIDENT AND APPOINTMENT OF HONORARY PRESIDENT

The Board hereby announces that, with effect from January 10, 2023:

1. Mr. Liu Xinwei has been appointed as the co-chief executive officer of the Company and ceased to act as the chief financial officer of the Company;

2. Ms. Li Wenqi has been appointed as the chief financial officer of the Company and ceased to act as the vice president of the Company; and

3. Mr. Zhang Jianjun has resigned as the president of the Company and been appointed as the honorary president of the Company.

APPOINTMENT OF CO-CHIEF EXECUTIVE OFFICER

The board (the “ Board ”) of directors (the “ Director(s) ”) of Gaush Meditech Ltd (the “ Company ”, together with its subsidiaries, the “ Group ”) is pleased to announce that, with effect from January 10, 2023, Mr. Liu Xinwei (劉新偉) (“ Mr. Liu ”), currently an executive Director and the chief financial officer (the “ Chief Financial Officer ”) of the Company, has been appointed as the co-chief executive officer (the “ Co-CEO ”) of the Company. In light of Mr. Liu’s new role as the Co-CEO, Mr. Liu has ceased to act as the Chief Financial Officer with effect from January 10, 2023. Mr. Liu will remain as an executive Director.

– 1 –

The biographical details of Mr. Liu are set out as follows:

Mr. Liu, aged 41, has around nine years of experience in the medical industry. Mr. Liu joined the Group as the board secretary of Gaush Medical Corporation, a wholly owned subsidiary of the Company, in May 2016. Mr. Liu served as the Chief Financial Officer from December 2018 to January 2023. He has served as a Director since November 21, 2019 and was redesignated as an executive Director on November 18, 2021. Mr. Liu also holds directorship in Gaush Europe GmbH, Gaush Coöperatief U.A. and Gaush Teleon Ltd, all of which are wholly owned subsidiaries of the Company. Before joining the Group, from April 2013 to March 2016, Mr. Liu served as assistant to the president of Beijing Naton Group Co., Ltd. (北京納通 科技集團有限公司), a company engaged in the research and development, manufacturing and sales of orthopaedic products.

Mr. Liu received his master degree in business administration from Tsinghua University (清華 大學) in July 2013. He received his bachelor degree in information engineering from Zhejiang University (浙江大學) in June 2004. Mr. Liu holds a legal professional qualification (法律 職業資格) certificate issued by the Ministry of Justice of the People’s Republic of China (the “ PRC ”) in March 2013 and became a non-practising member of the Beijing Institute of Certified Public Accountants (北京註冊會計師協會) in April 2017.

Mr. Liu has entered into a service contract (the “ Service Contract ”) with the Company for his directorship and role as a senior management of the Company. The Service Contract may be renewed in accordance with the amended and restated memorandum and articles of association of the Company and the applicable laws, rules and regulations. No separate service contract will be entered into between the Company and Mr. Liu in respect of his appointment as a Co-CEO and the terms of the existing Service Contract remain unchanged. Pursuant to the Service Contract, the initial term of his appointment as an executive Director is three years commencing from December 12, 2022 or until the third annual general meeting of the Company since the date of his appointment as an executive Director, whichever is sooner, unless terminated by not less than one month’s prior notice in writing served by either party to the other and subject to retirement by rotation and re-election in accordance with the amended and restated memorandum and articles of association of the Company, and there is no specified term for his appointment as a Co-CEO. Mr. Liu is entitled to receive a total remuneration of RMB1,170,000 per annum, plus a discretionary management bonus, as determined by the Board after considering the recommendation of the remuneration committee of the Company with reference to his duties and responsibilities with the Company and prevailing market conditions.

As of the date of this announcement, Mr. Liu is deemed to be interested in 955,879 shares of the Company (the “ Shares ”), representing approximately 0.65% of the total issued Shares.

Saved as disclosed above and as of the date of this announcement, Mr. Liu has confirmed that (i) he did not hold any directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (ii) he did not have any other relationship with any Director, senior management or substantial shareholders or controlling shareholders of the Company; (iii) he was not interested or deemed to be interested in any other Shares, underlying shares or debentures of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (iv) he did not hold other positions within the Group; (v) there is no other information that is

– 2 –

required to be disclosed pursuant to any of the requirements under Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited; and (vi) there is no other matters that need to be brought to the attention of the shareholders of the Company relating to Mr. Liu’s appointment as the Co-CEO.

APPOINTMENT OF CHIEF FINANCIAL OFFICER

The Board is pleased to further announce that Ms. Li Wenqi (李文奇) (“ Ms. Li ”), currently the vice president (the “ Vice President ”) and a joint company secretary of the Company, has been appointed as the Chief Financial Officer with effect from January 10, 2023. In light of Ms. Li’s new role as the Chief Financial Officer, Ms. Li has ceased to act as the Vice President with effect from January 10, 2023. Ms. Li will remain as a joint company secretary of the Company.

Ms. Li has confirmed that she has no disagreement with the Board and she is not aware of any matters in connection with her resignation of the Vice President that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited.

The biographical details of Ms. Li are set out as follows:

Ms. Li, aged 49, has over 20 years of experience in accounting and financial management. She first joined the Global Vision Corporation, a wholly owned subsidiary of the Company, in August 1998 and served successively as cashier, accountant, financial supervisor, financial manager and financial controller. She has served as the Vice President from January 2018 to January 2023 and was appointed as a joint company secretary of the Company on November 18, 2021.

Ms. Li received her bachelor’s degree in accounting from Beijing Wuzi University (北京物資 學院) in the PRC in July 1995. She also obtained accounting specialist qualification conferred by the Ministry of Finance of the PRC in May 1999.

RESIGNATION OF PRESIDENT AND APPOINTMENT OF HONORARY PRESIDENT

The Board further announces that Mr. Zhang Jianjun (張建軍) (“ Mr. Zhang ”) has resigned as the president (the “ President ”) of the Company with effect from January 10, 2023, due to his age. Upon the resignation, Mr. Zhang will remain as an executive Director. In view of Mr. Zhang’s efforts and valuable contributions to the Company during his tenure of office as the President, he has been appointed as the honorary president (the “ Honorary President ”) of the Company with effect from January 10, 2023. As the Honorary President, Mr. Zhang will assist Mr. Gao Tieta, the chairman of the Board, to share responsibility for coordinating designated works regarding, among others, strategic clients, significant public affairs, cultural construction and personnel development.

– 3 –

Mr. Zhang has confirmed that he has no disagreement with the Board and he is not aware of any matters in connection with his resignation of the President that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited.

By order of the Board Gaush Meditech Ltd Mr. Gao Tieta Chairman and Executive Director

Hong Kong, January 10, 2023

As of the date of this announcement, the Board comprises Mr. Gao Tieta as Chairman and executive Director, Mr. Zhang Jianjun, Mr. Liu Xinwei and Mr. Zhao Xinli as executive Directors, Dr. David Guowei Wang and Mr. Shi Long as non-executive Directors, and Mr. Feng Xin, Mr. Wang Li-Shin and Mr. Chan Fan Shing as independent non-executive Directors.

– 4 –